A Randomized, Open-Label, Single Oral Dose, Three-Way Cross-Over Trial to Evaluate the Relative Bioavailability of CVN424 Suspension &Tablet Formulations Including an Assessment of the Effect of Food on the Tablet Formulation in Healthy Adult Volunteers
Latest Information Update: 20 Aug 2024
At a glance
- Drugs Solengepras (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Cerevance
Most Recent Events
- 05 Dec 2022 New trial record